TL;DR
A comprehensive overview on CDH17 expression in human tumors identified various tumor entities that might often benefit from anti-CDH17 therapies and suggest utility of CDH17 IHC for the distinction of metastatic gastrointestinal or bilio-pancreatic adenocarcinomas from primary pulmonary adenocarcinomas.
AI-generated by Semantic Scholar
Authors
Frank Jacobsen, Ramesh Pushpadevan, Florian Viehweger, Morton Freytag, Ria Schlichter, Natalia Gorbokon, Franziska Büscheck, Andreas M. Luebke, Devita Putri, Martina Kluth, Claudia Hube-Magg, Andrea Hinsch, Doris Höflmayer, Christoph Fraune, Christian Bernreuther, Patrick Lebok, Guido Sauter, Sarah Minner, Stefan Steurer, Ronald Simon, Eike Burandt, David Dum, Florian Lutz, Andreas H. Marx, Till Krech, Till S. Clauditz
